



BICYCLE THERAPEUTICS IS NAMED WINNER OF BUSINESS WEEKLY'S DISRUPTIVE TECHNOLOGY AWARD 2017

CAMBRIDGE, U.K. and CAMBRIDGE, MASS. – MARCH 29, 2017 – Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (*Bicycle*[®]) product platform, announced today that it has been named by *Business Weekly* as the winner of its 2017 Disruptive Technology Award.

Bicycles are a new class of medicines designed to overcome the limitations of existing drug modalities. They exhibit the affinity and exquisite target specificity usually associated with antibodies but in a small molecule format, enabling rapid tissue penetration and flexible routes of administration. *Bicycles* can be used as standalone therapeutic entities or coupled to deliver a variety of therapeutic payloads, including potent cytotoxins, immune modulators, small molecule NCEs, radionuclides or nucleic acids.

“We are pleased to be recognized by *Business Weekly* for our innovative product platform and its potential to transform the therapeutic areas where it is being applied,” said Kevin Lee, Ph.D., Bicycle’s Chief Executive Officer. “This is the first time a life science company has won this prestigious award, which underscores the great potential of our platform and our ability to develop first in class therapeutics. We are rapidly advancing our pipeline and, with the support of Cancer Research UK, we expect to bring our lead molecule (BT1718) into the clinic this year to treat cancers with high unmet medical need.”

About Bicycle Therapeutics

Bicycle Therapeutics is developing a new class of medicines to treat oncology and other debilitating diseases based on its proprietary bicyclic peptide (*Bicycle*[®]) product platform.

Bicycles exhibit an affinity and exquisite target specificity usually associated with antibodies, while a low molecular weight delivers rapid and deep tissue penetration enabling more efficient tumour targeting. Their peptidic nature provides a “tuneable” pharmacokinetic half-life and a renal route of clearance, avoiding the liver and gastrointestinal tract toxicities often seen with other drug modalities. Bicycle Therapeutics is rapidly advancing towards the clinic with its lead molecule, BT1718, and is collaborating in oncology and other areas to realise the full potential of the technology. Bicycle Therapeutics’ unique intellectual property is based on the work initiated at the MRC Laboratory of Molecular Biology in Cambridge, U.K., by the scientific founders of the company, Sir Gregory Winter and Professor Christian Heinis. Bicycle Therapeutics is headquartered in Cambridge, U.K., with a U.S. subsidiary in Cambridge, Massachusetts. For more information, visit www.bicycletherapeutics.com.

Contacts:

Ten Bridge Communications (U.S.)
Sarah Sutton
Sarah@tenbridgecommunications.com
+1-857-242-1619

Consilium Strategic Communications (EU)
Mary-Jane Elliott / Chris Gardner / Ivar Milligan
Bicycle@consilium-comms.com
+44 20 3709 5700